{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:26:51Z","timestamp":1789586811979,"version":"build-2803163510"},"reference-count":22,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2021,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>\n                      To evaluate the efficacy of topical lotilaner ophthalmic solution, 0.25%, in patients with\n                      <jats:italic toggle=\"yes\">Demodex<\/jats:italic>\n                      blepharitis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Eighteen adults with\n                      <jats:italic toggle=\"yes\">Demodex<\/jats:italic>\n                      blepharitis, defined as &gt;10 collarettes on the upper lid and\/or mite density of \u22651.5 mites per lash (upper and lower), were treated bid for 42 days with the topical lotilaner ophthalmic solution, 0.25%. Contact lens wear, artificial eyelashes, and lid structural abnormalities were among the exclusion criteria. No other antibacterial, antiparasitic, or anti-inflammatory treatment or lid hygiene products were permitted. One eye of each patient was selected for analysis and assessed on day 7, 14, 28, and 42. Collarettes were graded at each visit, and mite density was evaluated by microscopy at each visit except day 7. Outcome measures were collarette elimination (\u22642 lashes with collarettes) and mite eradication (0 mites). Drop tolerability, adverse events, visual acuity, and slit-lamp biomicroscopy were assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Collarette elimination was achieved in 13\/18 participants (72.2%) by day 42. Mean collarette grade (upper lid) declined from 3.56\u2009\u00b1\u20090.17 to 0.28\u2009\u00b1\u20090.11. Mite eradication was achieved in 14\/18 participants (77.8%) by day 42. Mean mite density decreased from 2.63\u2009\u00b1\u20090.39 to 0.12\u2009\u00b1\u20090.08 mites\/lash. Participants reported good tolerability. Adverse events were mild and transient and did not result in treatment discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      Six weeks of at-home topical therapy with the lotilaner ophthalmic solution, 0.25%, was effective in eliminating the most common objective signs of\n                      <jats:italic toggle=\"yes\">Demodex<\/jats:italic>\n                      blepharitis, with a collarette elimination rate of 72% and mite eradication in 78% of eyes by day 42. ISRCTN registration #: 24398865\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2021.0011","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T15:56:30Z","timestamp":1629474990000},"page":"479-484","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":18,"title":["Collarette Elimination and\n                    <i>Demodex<\/i>\n                    Mite Eradication with Topical Lotilaner Ophthalmic Solution, 0.25%"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6654-5191","authenticated-orcid":false,"given":"Roberto","family":"Gonzalez-Salinas","sequence":"first","affiliation":[{"name":"Asociaci\u00f3n para Evitar la Ceguera en Mexico I.A.P., Mexico City, Mexico."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Yeu","sequence":"additional","affiliation":[{"name":"Virginia Eye Consultants, Norfolk, Virginia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Holdbrook","sequence":"additional","affiliation":[{"name":"Tarsus Pharmaceuticals, Inc., Irvine, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie N.","family":"Baba","sequence":"additional","affiliation":[{"name":"Tarsus Pharmaceuticals, Inc., Irvine, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Ceballos","sequence":"additional","affiliation":[{"name":"Asociaci\u00f3n para Evitar la Ceguera en Mexico I.A.P., Mexico City, Mexico."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Massaro-Corredor","sequence":"additional","affiliation":[{"name":"Asociaci\u00f3n para Evitar la Ceguera en Mexico I.A.P., Mexico City, Mexico."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Corredor-Ortega","sequence":"additional","affiliation":[{"name":"Asociaci\u00f3n para Evitar la Ceguera en Mexico I.A.P., Mexico City, Mexico."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nallely","family":"Ramos-Betancourt","sequence":"additional","affiliation":[{"name":"Asociaci\u00f3n para Evitar la Ceguera en Mexico I.A.P., Mexico City, Mexico."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Quiroz-Mercado","sequence":"additional","affiliation":[{"name":"Asociaci\u00f3n para Evitar la Ceguera en Mexico I.A.P., Mexico City, Mexico."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,10,4]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-018-0624-3"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1963.01590210056008"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e32833df9f4"},{"key":"e_1_3_4_5_2","author":"Zhong J.","unstructured":"Zhong J., , Tan Y., , Li S., et al. The prevalence of Demodex folliculorum and Demodex brevis in cylindrical dandruff patients. J. Ophthalmol. 8949683, 2019.","journal-title":"J. Ophthalmol."},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.05-0275"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000168"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.11.131"},{"key":"e_1_3_4_9_2","author":"Toutain C.E.","unstructured":"Toutain C.E., , Seewald W., , and Jung M. The intravenous and oral pharmacokinetics of lotilaner in dogs. Parasit Vectors 10:522\u2013529, 2018.","journal-title":"Parasit Vectors"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1801338115"},{"key":"e_1_3_4_11_2","author":"Gonzalez-Salinas R.","unstructured":"Gonzalez-Salinas R., , Yeu E., , Holdbrook M., et al. Safety and efficacy of topical lotilaner 0.25% ophthalmic solution for the treatment of Demodex blepharitis: A pilot study. J Ophthalmol 2021 [In press].","journal-title":"J Ophthalmol"},{"key":"e_1_3_4_12_2","author":"Gonzalez-Salinas R.","unstructured":"Gonzalez-Salinas R., , Karpecki P., , Yeu E., et al. Safety and efficacy of lotilaner ophthalmic solution, 0.25% for the treatment of blepharitis due to demodex infestation: A randomized, controlled, double-masked clinical trial; Cont Lens Anterior Eye 2021 [Epub ahead of print]; DOI: 10.1016\/j.clae.2021.101492.","journal-title":"Cont Lens Anterior Eye"},{"key":"e_1_3_4_13_2","first-page":"1","article-title":"The hair follicle mites Demodex folliculorum and Demodex brevis: biology and medical importance","volume":"162","author":"Rufli T.","year":"1981","unstructured":"Rufli T., , and Mumcuoglu Y. The hair follicle mites Demodex folliculorum and Demodex brevis: biology and medical importance. A review. Dermatologica., 162:1\u201311, 1981.","journal-title":"A review. Dermatologica."},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTO.S142708"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2012.27.12.1574"},{"key":"e_1_3_4_16_2","first-page":"CD013333","article-title":"Tea tree oil for Demodex blepharitis","volume":"6","author":"Savla K.","year":"2020","unstructured":"Savla K., , Le J.T., , and Pucker A.D. Tea tree oil for Demodex blepharitis. Cochrane Database Syst. Rev. 6:CD013333, 2020.","journal-title":"Cochrane Database Syst. Rev"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ico.0000244870.62384.79"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S144483"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000415"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.2007.00341.x"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/10412905.1997.9700780"},{"key":"e_1_3_4_22_2","author":"Loughlin R.","unstructured":"Loughlin R., , Gilmore B.F., , McCarron P.A., , and Tunney M.M. Comparison of the cidal activity of tea tree oil and terpinent-4-ol against clinical bacterial skin isolates and human fibroblast cells. Lett. Appl. Microbiol. 46;428\u2013433, 2008.","journal-title":"Lett. Appl. Microbiol"},{"key":"e_1_3_4_23_2","author":"Chen D.","unstructured":"Chen D., , Wang J., , Sullivan D.A., , Kam W.R., , and Liu Y. Effects of terpinen-4-ol on meibomian gland epithelial cells in vitro. Cornea. 2020. [Epub ahead of print].","journal-title":"Cornea"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2021.0011","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2021.0011","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2021.0011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:44:33Z","timestamp":1777646673000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2021.0011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,10,1]]}},"alternative-id":["10.1089\/jop.2021.0011"],"URL":"https:\/\/doi.org\/10.1089\/jop.2021.0011","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,1]]}}}